CMS Administrator Dr. Mehmet Oz wants Medicare beneficiaries to know they can now get weight-loss drugs for $50 a month, and he argues the move will save taxpayers money by cutting the chronic disease costs that devour the federal health budget.
In an exclusive interview with Fox News Digital at the Great American State Fair in Washington, D.C., on July 6, Oz laid out his vision for GLP-1 medications as a tool to break the cycle of obesity-driven illness that he says accounts for the vast majority of government healthcare spending.
The interview came days after the Medicare GLP-1 Bridge Program officially opened enrollment. The temporary pilot runs through December 31, 2027, and offers eligible seniors brand-name GLP-1 weight-loss drugs, including Eli Lilly's Foundayo and Zepbound and Novo Nordisk's Wegovy, at a flat $50 monthly co-pay. It is the first time most older Americans can get these medications covered by insurance strictly for weight loss.
Oz did not mince words about the fiscal math. He told Fox News Digital that roughly 70 percent of all U.S. healthcare spending goes to chronic conditions, and that obesity sits at the top of the list.
"We think about 70% of all the money we spend on healthcare is caused by chronic conditions, and [obesity] is the No. 1 driver of all that, so it's a smart decision."
That framing puts the Bridge Program squarely inside the administration's broader effort to rein in federal health expenditures by attacking root causes rather than managing downstream symptoms. If fewer seniors develop diabetes, high blood pressure, and heart disease, the argument goes, Medicare pays less over time.
Oz said he believes the drugs will pay for themselves:
"We believe these are so effective in reducing conditions like high blood pressure and diabetes that they'll actually save money for the federal taxpayer, because [they're] going to make you healthy enough that you don't have to consume health services."
It is a bold claim, and one that will face scrutiny. The Washington Examiner reported that projections show a potential $48 billion net cost over ten years if the program scales up. Major insurers including CVS and UnitedHealthcare have already declined to participate in a longer-term follow-on program called "Balance," citing cost concerns. CMS Director of Medicare Chris Klomp told reporters the agency expects "single-digit million" initial enrollment and added, "We'll see where it scales over time."
The Bridge Program is not a blanket entitlement. Eligibility requires a body mass index of 35 or higher, or a BMI of 27 or higher alongside qualifying health conditions such as a prior heart attack, stroke, or prediabetes. Seniors already receiving GLP-1 drugs for diabetes or sleep apnea do not qualify. A doctor must provide prior authorization.
Roughly 4 million Medicare beneficiaries meet the criteria, Breitbart reported, citing program details. Oz acknowledged in the Fox News Digital interview that the existing Medicare framework already covers certain GLP-1 drugs for overweight patients with conditions like high blood pressure and diabetes. The Bridge Program is designed to reach those who fall outside that box.
"There are a lot of overweight people who don't have high blood pressure, diabetes or other conditions, so they don't get access to the drug normally. We want them to have the ability to use it as well."
The program sidesteps a federal law that prohibits Medicare from covering drugs prescribed solely for obesity. By structuring it as a temporary demonstration project, CMS created a legal pathway without waiting for Congress to act, a move that reflects the administration's preference for executive initiative over legislative gridlock.
Even with the program now live, most seniors do not know it exists. A survey cited by Newsmax found that 82 percent of adults 65 and older had not heard of the Medicare GLP-1 Bridge Program. That gap matters. Twenty-seven percent of older adults surveyed said they medically qualify for obesity treatment, and among those who qualify, 82 percent said Medicare coverage of GLP-1 drugs is "essential."
Sixty-one percent of respondents told the Obesity Care Advocacy Network that Medicare should cover obesity treatment the same way it covers other chronic diseases. The demand is there. The information is not reaching the people who need it.
One beneficiary put the frustration in personal terms. Katie Smith, a 71-year-old Virginia Medicare enrollee, told the Associated Press:
"I cannot tell you how frustrated I am. I have the drive and I have the willingness and I have the motivation, but I have not been able to lose weight in all the conventional ways."
Stories like Smith's illustrate why Oz has pushed to lower cost barriers. At the program's launch, he declared: "The sheer cost of these medications is a huge barrier to access. That ends today."
To his credit, Oz did not treat GLP-1 drugs as a magic fix. He described them as a supplement to the basics, not a substitute.
"I'm a fan of GLP-1 drugs when used correctly. They do help people who are overweight lose weight quite effectively. They're not a replacement for diet and exercise, but they might jumpstart the system so it's easier for you to use healthier tactics."
He went further, pointing to lifestyle choices as the real foundation of health, and framing that message in language that sounded less like a government administrator and more like a doctor talking to a patient.
"I love the fact that the innovation that's coming out of pharmaceutical companies is allowing us to save lives and make lives better. But the real [secret to longevity] is eating right, exercising, sleeping, dealing with the stress of your life, finding some purpose in your existence [and] realizing you have agency over the future."
He added, with characteristic directness:
"These are things that your mom would have told you [and that] you don't need a doctor to be emphasizing."
That blend, pharmaceutical innovation plus personal responsibility, tracks with the broader MAHA agenda the administration has promoted. Oz explicitly connected the two, saying that using every available tool to care for one's body, "which includes using medications when appropriate," is what the movement means to him.
Oz also struck a tone that conservatives do not always associate with government health officials. He pushed back against fat-shaming while still urging action.
"I don't want people being fat-shamed... I don't want you feeling guilty that you're gaining weight even though everyone else around you seems to have figured it out. It's not that simple, our set points for hunger are different. We have different things going on in our lives."
But he paired that empathy with a call to treat the body as something worth fighting for:
"But if you realize how precious you are, the temple of the soul is so valuable. It's the greatest gift your parents ever gave you, and you take advantage of every tool out there to make it work... which includes using medications when appropriate."
The Bridge Program runs through 2027. What happens after that remains unclear. The longer-term "Balance" program that CMS envisioned has struggled to attract insurer participation. If private plans will not share the risk, taxpayers will face a choice: absorb the full cost, scale back, or let the program expire.
The $48 billion ten-year cost projection looms large. Oz's argument that GLP-1 drugs will reduce downstream spending is plausible in theory, fewer diabetics, fewer heart attacks, fewer hospitalizations. But that payoff takes years to materialize, and Washington is not known for patience with long-term bets.
There are also practical questions the program's rollout has not fully answered. Which specific drugs qualify beyond the three named brands? What happens if drug prices shift? And how does CMS plan to close the 82-percent awareness gap among the very seniors the program is designed to help?
For now, the administration has placed a concrete bet: that giving seniors affordable access to weight-loss drugs will bend the cost curve on chronic disease. The pilot will generate data. The data will either vindicate the theory or expose its limits.
Government programs that promise to save money by spending money have a long and mixed track record. But at least this one starts from an honest premise: that obesity is expensive, chronic disease is bankrupting Medicare, and doing nothing costs plenty too.
